Qulipta Cost in 2026: Prices & How to Save
Qulipta Cost in 2026: Prices & How to Save
Your neurologist writes the prescription, you feel hopeful for the first time in months, and then the pharmacy quotes you $1,572 for thirty tablets. That's roughly $52 a day to not have a migraine.
The Qulipta cost problem is not going away on its own, either. There's no generic, and based on the current patent estate, there won't be one for years. But the price you get quoted at a US retail counter is only one of several numbers attached to this drug, and it's the highest one.
At a glance
- Qulipta's average US retail price is about $1,572 for 30 tablets — roughly $19,000 a year.
- The manufacturer's list price (WAC) is $1,204.57 as of January 2026, up from $991 in January 2022.
- All three strengths — 10 mg, 30 mg, and 60 mg — cost about the same, so cutting your dose won't cut your bill.
- There is no generic atogepant, and patent protections currently run to January 2035.
- Cash-pay pricing through CanAmerica Plus is $587.99 for a 30-tablet supply, a little over a third of US retail.
How much does Qulipta cost without insurance in 2026?
Qulipta (atogepant) is a once-daily oral CGRP receptor antagonist — a gepant — approved to prevent both episodic and chronic migraine. It's a preventive, taken every day whether or not you have an attack, which means the monthly price is the price. There's no rationing it to bad weeks.
What you'll actually be quoted depends entirely on where you fill it:
| Where you fill it | Qulipta cost (30 tablets) | Per day |
|---|---|---|
| Average US retail, no insurance | ~$1,572 | ~$52 |
| Manufacturer list price (WAC, Jan 2026) | $1,204.57 | ~$40 |
| Amazon Pharmacy retail | ~$1,450 | ~$48 |
| GoodRx / SingleCare discount price | ~$953–$1,172 | ~$32–$39 |
| CanAmerica Plus (cash-pay) | $587.99 | ~$20 |
That's a spread of nearly $1,000 a month for the identical medication. Over a year, the difference between the retail quote and the cash-pay price is close to $12,000.
Does a lower dose cost less?
No — and this catches people out. Qulipta comes in 10 mg, 30 mg, and 60 mg tablets, and US pricing is essentially flat across all three. Discount-price listings put 30-tablet supplies of both the 30 mg and 60 mg strengths within a few cents of each other, around $1,463 at retail.
So if you and your neurologist step down from 60 mg to 30 mg because the higher dose upset your stomach, expect your pharmacy bill to stay put. Dose reduction is a clinical decision here, not a financial one.
Why is Qulipta so expensive?
AbbVie holds exclusivity, and it has used it. The Wholesale Acquisition Cost for a 30-day supply was $991.00 in January 2022. As of January 2026 it's $1,204.57 — a 21.6% increase in four years, on a drug that faces no generic competition.
That last part is the real driver. Qulipta is protected by eight patents, and while the drug became eligible for patent challenges on September 28, 2025 — and at least one Paragraph IV challenge has been filed — the earliest projected date for generic entry is currently January 30, 2035. Patent litigation could move that date, but nobody should plan a household budget around it.
Is there a generic for Qulipta?
Not yet, and not soon. Atogepant is available only as brand-name Qulipta in the United States.
This matters more than it might seem. When a drug has a generic, the cheapest path is almost always the generic at a US pharmacy. When it doesn't, the cheapest path is usually the brand-name product sourced through a cash-pay channel, because US retail pricing for brand-only drugs sits far above what the same medication costs almost anywhere else. Qulipta is squarely in the second category.
Savings tip: Before you accept a pharmacy quote on any brand-only drug, price it through a cash-pay network and compare. On medications with no US generic, that comparison is where the largest savings usually turn up — and it takes about two minutes.
Qulipta cost with insurance and Medicare
Coverage is inconsistent, which is why so many people end up looking at the cash price anyway.
Most commercial plans do list Qulipta on their formulary, but a large share put it behind prior authorization, step therapy, or both. Step therapy means your insurer wants documentation that you tried and failed cheaper preventives first — typically a generic like topiramate or propranolol — before it will pay for a gepant. Some plans require two or three failed trials.
Medicare Part D works the same way, plan by plan. Some Part D formularies cover Qulipta; others exclude it entirely. Even when it's covered, it usually sits on a specialty or non-preferred brand tier, where coinsurance is a percentage of the drug's cost rather than a flat copay. On a $1,200 drug, 25% coinsurance is $300 a month.
Two practical steps: pull your plan's formulary and look up Qulipta by tier, and ask your neurologist's office whether they've already documented failed preventive trials in your chart. That documentation is what prior authorizations turn on.
How Qulipta compares to other migraine preventives
Most cost comparisons stop at the CGRP class, which makes Qulipta look mid-priced. Widen the frame to every preventive option and the picture changes a lot.
| Preventive | Type | Typical US retail | Notes |
|---|---|---|---|
| Qulipta (atogepant) | Oral gepant, daily | ~$1,572/mo | No generic |
| Aimovig (erenumab) | Monthly injection | ~$1,030/mo | No generic |
| Emgality (galcanezumab) | Monthly injection | ~$993/mo | No generic |
| Ajovy (fremanezumab) | Monthly/quarterly injection | ~$1,000/mo | No generic |
| Vyepti (eptinezumab) | IV infusion, quarterly | ~$1,665/dose | Infusion center fees extra |
| Topamax / topiramate | Oral, daily | Generic widely available | $57.99 per 100 tablets cash-pay |
| Propranolol | Oral beta blocker, daily | Generic widely available | $55.99 per 100 tablets cash-pay |
| Amitriptyline | Oral, daily | Generic widely available | Older option, often very cheap |
The generics at the bottom of that table cost a rounding error compared to the gepants and the anti-CGRP antibodies. They also come with side effects — topiramate's cognitive fog and tingling, propranolol's fatigue — that push plenty of people toward the newer drugs for good reason.
The honest framing: if you haven't tried a generic preventive, it's worth a conversation with your prescriber, both because your insurer may require it and because it might work. If you've already been through them, the newer drugs aren't a luxury and you shouldn't feel talked into a step backward.
Worth noting separately: Qulipta is a preventive, while Ubrelvy (ubrogepant) and Nurtec ODT (rimegepant) treat attacks that have already started. Nurtec straddles both. People often compare their prices side by side without realizing they're solving different problems.
What you're actually paying per migraine day prevented
This is the calculation nobody publishes, and it's the one that tells you whether the price makes sense for you.
In the phase 3 ADVANCE trial, people with episodic migraine taking 60 mg of atogepant saw monthly migraine days drop by 4.2, compared with 2.48 on placebo — a placebo-adjusted benefit of about 1.7 days a month. In the PROGRESS trial for chronic migraine, 60 mg cut monthly migraine days by 6.9 versus 5.1 for placebo.
Run the money against those numbers:
- At US retail ($1,572/month): about $374 per migraine day avoided using the absolute reduction, or roughly $925 per day using the placebo-adjusted figure.
- At cash-pay ($587.99/month): about $140 per migraine day avoided, or roughly $346 placebo-adjusted.
Neither number is small. But there's a meaningful difference between paying $140 for a day you'd otherwise have lost and paying $925 for it — and that difference is entirely about where you buy, not about the drug.
Ways to lower your Qulipta cost
Price the cash-pay option before you fill. A 30-tablet supply of Qulipta runs $587.99 through CanAmerica Plus, against roughly $1,572 at average US retail. Same medication, sourced through licensed pharmacies. Compare it against your actual copay, not against the sticker price — if your insurance copay is $40, keep the insurance.
Ask for a 90-day supply. Fewer fills usually means lower per-unit cost and fewer shipping or dispensing fees, and it protects you against mid-year price changes on a drug whose list price has moved repeatedly in four years.
Check more than one pharmacy. US retail pricing on the same drug can vary by hundreds of dollars between pharmacies a few miles apart. Call three before you commit to one.
Get the prior authorization done properly the first time. Most denials come down to missing documentation of prior preventive trials, not a coverage exclusion. Ask the prescriber's office to submit the trial history with the initial request rather than after an appeal.
Ask whether a generic preventive belongs in the plan. Not as a replacement if you've already failed them — but if you haven't, a $58 bottle of topiramate that lasts three months is worth ruling out first.
Whatever route you take, verify you're dealing with a licensed, accredited pharmacy. Prices well below every legitimate cash-pay option are a warning sign, not a bargain.
The bottom line
Qulipta costs about $1,572 a month at US retail in 2026, with no generic on the horizon before 2035 and a list price that has climbed 21.6% since 2022. Insurance coverage exists but frequently sits behind step therapy and specialty-tier coinsurance.
The single largest lever available to most people is the purchase channel: cash-pay pricing puts the same 30 tablets at $587.99. Before your next fill, price it both ways and bring the numbers to your neurologist — especially if a denied prior authorization is what put you in front of the retail price in the first place.
Frequently asked questions
How much does Qulipta cost per month without insurance?
About $1,572 for a 30-tablet supply at average US retail, which works out to roughly $52 a day or around $19,000 a year. Discount card prices land near $953 to $1,172, and cash-pay pricing through CanAmerica Plus is $587.99 for the same 30 tablets.
Is there a generic version of Qulipta?
No. Atogepant is sold only as brand-name Qulipta in the US. Eight patents protect the drug, and the earliest projected generic entry date is January 30, 2035, though pending patent challenges could change that.
Does Medicare cover Qulipta?
It depends on your Part D plan. Some formularies include it, some don't, and even covered plans typically place it on a specialty or non-preferred tier with percentage-based coinsurance rather than a flat copay. Check your specific plan's formulary before assuming either way.
Is Qulipta cheaper at 30 mg than at 60 mg?
Generally no. US pricing is close to flat across the 10 mg, 30 mg, and 60 mg strengths, so lowering your dose won't lower your cost. Dose changes should be made for tolerability and effectiveness, with your prescriber.
How does Qulipta's cost compare to Nurtec or Ubrelvy?
They're priced in the same range but treat migraine differently. Qulipta is a daily preventive at roughly $1,572 a month retail. Ubrelvy and Nurtec are taken during an attack, so your monthly spend depends on how many attacks you treat — which can be higher or lower than a preventive depending on your migraine frequency.
This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider for diagnosis and treatment. Pricing information is current as of the publication date but may change. Verify pricing directly before making purchasing decisions.